GLO Science, LLC, introduces the GLO Brilliant™ Personal Teeth Whitening Device—available in Sephora stores nationwide and on Sephora.com—today, Thursday May 12. The Smile Revolution™ is here!
The GLO Brilliant™ Personal Teeth Whitening Device uses a patent-pending Guided Light Optics (GLO) technology for superior, at-home whitening results without sensitivity. GLO™ Whitening combines the innovative, patented GLO Brilliant™ Mouthpiece partnered with the unique G-Vial whitening gel delivery system to accelerate the whitening process. Now you can decide where, when, how long, and how often to whiten, without sensitivity. The payoff is teeth that are as white and bright as can be, simply put it on, press power—and GLO.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/glo/50090/
Joerns Healthcare has launched the Dolphin Fluid Immersion Simulation® system that more effectively prevents and treats pressure-related injuries than other surfaces. This patented technology simulates the effect of floating in water for patients on hospital beds, stretchers, and in wheel chairs. The Dolphin technology continually adjusts to the patient’s body, promoting tissue perfusion and oxygenation, and minimizing injury related to compromised blood flow. The Dolphin is also proven to accelerate healing of advanced stage or multiple pressure ulcers, muscle flaps, skin grafts, burns and other wound conditions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58463-joerns-dolphin-fluid-immersion-simulation-system-pressure-related-injuries
ConnXus, a supplier diversity technology platform, today announced that it has closed $5 million in Series “A” funding, led by Techstars Ventures, Serious Change L.P. and Impact America Fund.
“This round of funding will significantly accelerate ConnXus’ long-term impact on generating sustainable and diverse supply chains,” said Rod Robinson, CEO and founder of ConnXus. “To date we’ve raised $10 million in investments, including participation from Techstars Ventures, CincyTech, Serious Change L.P., Impact America Fund, and several private angel investors.”
ConnXus’ cloud-based, supplier diversity sustainability dashboards open the door for procurement, supplier diversity, and supply chain professionals to access a wealth of global supply chain analytics. Robinson believes Techstars and the other investors are the right investors for the company to disrupt and add imperative value to the $10-billion supply chain and procurement software market.
To view the multimedia release go to:
http://www.multivu.com/players/English/7834951-connxus-five-million-series-a/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Quadriplegic former IndyCar driver and current team owner Sam Schmidt completed the bottom half of the challenging, high-altitude Broadmoor Pikes Peak International Hill Climb yesterday in the Arrow Electronics, Inc. (NYSE:ARW) Semi-Autonomous Motorcar (SAM car).
Schmidt, who was paralyzed from the neck down in a crash during an IndyCar practice lap in 2000, is able to steer, accelerate and brake the modified 2016 Corvette Z06 SAM car using only his head. Sensors mounted on an Arrow-designed high-tech headset that Schmidt wears connect to infrared cameras mounted on the dashboard and detect his head-tilt motions to steer. A sip-and-puff device that Smith breathes into enables him to accelerate and brake.
Daimler AG, Ford Motor Company and Nissan Motor Co., Ltd., have signed a unique three-way agreement to accelerate the commercialization of fuel cell electric vehicle (FCEV) technology.
The goal of the collaboration is to jointly develop a common fuel cell electric vehicle system while reducing investment costs associated with the engineering of the technology. Each company will invest equally towards the project. The strategy to maximize design commonality, leverage volume and derive efficiencies through economies of scale will help to launch the world’s first affordable, mass-market FCEVs as early as 2017.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58680-renault-nissan-daimler-ford-partnership
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
The American Cancer Society and the CVS Health Foundation today awarded grants to 20 U.S. colleges and universities as part of their Tobacco-Free Generation Campus Initiative (TFGCI), a $3.6 million multi-year program intended to accelerate and expand the adoption and implementation of 100 percent smoke- and tobacco-free campus policies. The announcement coincides this week with the American Cancer Society Great American Smokeout.
The Tobacco-Free Generation Campus Initiative is part of Be The First, CVS Health's five-year, $50 million initiative that supports education, advocacy, tobacco control, and healthy behavior programming to help deliver the nation’s first tobacco-free generation. CVS Health has set actionable and measurable goals for Be The First, including a doubling of the number of tobacco-free college and university campuses in the United States.
To view the multimedia release go to:
http://www.multivu.com/players/English/7963951-cvs-health-tobacco-free-campus/
